FDA Grants Priority Review to Cogent’s Bezuclastinib Combo for GIST
Event summary
- FDA accepted Cogent’s NDA for bezuclastinib + sunitinib in GIST with Priority Review, setting PDUFA date for November 30, 2026.
- Phase 3 PEAK trial showed median PFS of 16.5 months for combo vs. 9.2 months for sunitinib alone (HR=0.50, p<0.0001).
- Full PEAK trial results to be presented at ASCO on May 30, 2026.
- Bezuclastinib combo demonstrated 46% ORR in imatinib-resistant patients vs. 26% for sunitinib.
- Safety profile generally well-tolerated; no unique risks identified vs. sunitinib monotherapy.
The big picture
Cogent’s NDA acceptance marks a pivotal moment in GIST treatment, as bezuclastinib + sunitinib is the first therapy to demonstrate statistically significant advantage over an active comparator. The Priority Review designation reflects the unmet need in this rare cancer indication. Success here could position Cogent as a key player in precision oncology, particularly for genetically defined diseases driven by KIT mutations.
What we're watching
- Regulatory Timing
- Whether the FDA will meet the November 30, 2026 PDUFA date without advisory committee review.
- Commercialization Pace
- How quickly Cogent can launch bezuclastinib in both GIST and systemic mastocytosis post-approval.
- Competitive Positioning
- The impact of these results on existing GIST treatment standards and potential market share shifts.
Related topics